Article Type
Review
Published
This article reviews key second-line regimens recommended in major guidelines for treatment of patients with extensive-stage small cell lung cancer with platinum-sensitive relapse (chemotherapy-free interval ≥90 days), focusing on recent prospective clinical trials and post hoc analyses.